Our History

ExpreS2ion Biotechnologies ApS was founded in 2010, based on a decade-long research on developing an optimised protein expression system using Drosophila S2 cells. We call it the ExpreS2 platform. From over 20 years of using ExpreS2, the platform’s superiority to alternative systems when it came to the expression of complex proteins is well-documented.
In 2016, ExpreS2ion Biotech Holding AB was founded and listed on Nasdaq First North Stockholm, and in 2017 the joint venture company AdaptVac was established. AdaptVac has developed a capsid Virus-Like Particle (cVLP) platform that makes it possible to create next-generation vaccines and vaccine-like treatments, and it is thus perfect match for our ExpreS2 development and manufacturing platform.

Going forward, we are increasing our focus on advancing ExpreS2ion’s growing product development pipeline together with industrial and academic partners, while continuing to offer attractive discovery, development, and manufacturing services based on our platform and know-how.

Selected company events


Phase III validation of our ExpreS2™ antigen production system in conjunction with the VLP technology from AdaptVac


The ExpreS2 platform enters Phase III clinical trial settings for the first time when Bavarian Nordic initiates a Phase III trial for the ABNCoV2 COVID-19 booster vaccine.


ExpreS2ion announces positive topline results for its HER2-cVLP breast cancer vaccine, demonstrating animal proof-of-concept.

ExpreS2ion granted exclusive global license for HER2-cVLP breast cancer vaccine programme from AdaptVac.


ExpreS2ion announces successful proof of concept in animals for the cVLP COVID-19 vaccine.

The international next-generation influenza vaccine consortium INDIGO, with ExpreS2ion as a participating member, receives a 10 MEUR Horizon 2020 grant of which the company receives 0.6 MEUR directly.

The company and AdaptVac initiates a partly EU Horizon 2020-funded cVLP COVID-19 vaccine program together with the PREVENT-nCoV European consortium.


A ExpreS2-produced Zika Ns1 antigen becomes available from Virion/Serion.

HighMan-S2, a new glyco-engineered cell line under the GlycoX-S2™ platform, becomes commercially available.

A CRISPR-Cas technology license is obtained, enabling substantially improved gene-editing capabilities.


The Joint Venture AdaptVac is established, enabling the use of the ground-breaking Virus-Like Particle (VLP) technology to create next-generation vaccines and vaccine-like treatments in ExpreS2ion’s projects.


The ExpreS2ion share is listed on Nasdaq First North Growth Market in Stockholm, Sweden.


Approval for a clinical phase Ia study in Germany for the pregnancy-associated malaria vaccine project.


A scientific article, co-authored by ExpreS2ion researchers, is published in the renowned journal Nature.  

A multi-year research license is signed with the global pharmaceutical company Roche.

The first GMP (Good Manufacturing Practice) production batch of ExpreS2-produced proteins for malaria phase 1 clinical studies is manufactured.


Jenner Institute at the University of Oxford receives MRC and EVI contributions for preclinical RH5 malaria vaccine, developed on the ExpreS2 platform together with ExpreS2ion.


The company receives an HTF grant worth 3.5 MDKK together with University of Copenhagen and CMC Biologics for malaria research.


ExpreS2ion Biotechnologies ApS is founded.